MPN Updates

January 2016

Issue link:

Contents of this Issue


Page 0 of 28

A © 2016 SLACK Incorporated Introduction MPN Updates is a digital publication that focuses on current research and standards of care for patients with myeloproliferative neoplasms (MPNs). Each issue invites the reader to learn more about diagnosis and treatment options, including emerging ther- apeutic agents, as well as the impact MPNs have on patients. With MPNs being an extremely rare form of cancer, physicians need better ac- cess to information on available treatment options for patients with all types of MPNs, whether it be essential thrombocythemia, polycythemia vera or primary myelofi- brosis. Treatment options also vary widely based on the severity of the disease. is issue of MPN Updates focuses on the varied treatments for all types of MPNs, with a main goal of increasing quality of life for our patients. From aspirin regimens and gentle exercise, to JAK2 inhibitors and IN THIS ISSUE: MPN Updates ISSUE 3 | VOL 2 | JANUARY 2016 This newsletter is produced by SLACK Incorporated through a third-party independent grant by Incyte Corporation. 22 14 2 11 Disease impact on patient quality of life should inform MPN treatment 5 28 Treatment trajectory for MPN as unique as the disease itself 'Watch and wait' approach dependent upon each MPN case Patient Profile Physician, patient efforts needed for participation in MPN research VIDEO: Spivak shares thoughts on JAK2 inhibitors as treatment for MPNs

Articles in this issue

Links on this page

Archives of this issue

view archives of MPN Updates - January 2016